Four Democrat-Led States Ask FDA to Lift Restrictions on Abortion Pill

Public Prosecutor of Four States led by Democrats-New York, New Jersey, Massachusetts and California-Seam Food and Drug Administration on Thursday, June 5, asking the agency to lift what they consider unnecessary restrictions on MivePristone.

The petition aims to compel the food and drug management to recognize Strong clinical evidence And contracts from MivePristone use this Supporting the safety and effectiveness of the drug. The move comes only one month after the Minister of Health and Humanitarian Services Robert F. Kennedy Junior. He said Congress is the order to review the safety of miscarriages. A spokesman for the FDA certain Plan for the review in a statement by CBS News on Tuesday 3 June.

According to FDA,, MifePristone, approved by the organizer in 2000, is a drug that prevents progesterone, which is necessary for pregnancy to continue. It is commonly used with drug mesoprostol to end the pregnancy within 10 weeks of pregnancy.

Analysis of 2023 data by the Guttmacher Institute Find More than half (63 %) of all abortion in the United States, but in the years since then The Supreme Court canceled ROE V. Wade17 states have banned this drug, and 10 additional states have placed restrictions on it, according to Washington Post.

“The medicine is the lifeline for millions of women who need to obtain decisive health care-especially low-income women and those who live in rural areas and disadvantaged areas,” He said Los Angeles Times.

The petition specifically requires the FDA (FDA) to raise the risk assessment program and reduce the MifePristone (Rems). This additional organizational framework is designed to “help ensure the benefits of the drug that exceeds its risks,” he said. FDA. It was Rems Applied To 325 drugs from its inception and currently apply to 71 drugs.

Rems places multiple restrictions on the use of MivePristone, including placing characteristics on the lists of national and local abortion offices; Patients provide written data that intend to end their cases; Pharmacies maintain the records of descriptions and users. Public lawyers argue that these rules “impose unnecessary and exhausting obstacles on patients, recipes, pharmacists and a health care system.”

They also point out that MivePristone has been marketed in the United States decades ago and was safely used by more than 7.5 million American women. “Moreover, no new evidence appeared in safety concerns in the past two decades,” she says.

These countries are not alone in their endeavor to reach the MEPRISESTON. Seventeen other states led by democracy, in addition to Washington, DC prosecution The Food and Drug Administration in Spokan, Washington, to alleviate the drug restrictions, Reuters I mentioned In February. What’s more, with leading medical organizations The name The Food and Drug Administration is to remove REMS restrictions on MivePristone for years.

If the FDA (FDA) refuses to remove ReMS, the seam on Thursday requires the agency to “exercise its discretionary authority to not impose” some or all restrictions in New York, New Jersey, Massachusetts and California, as these states already place “strict restrictions” about medicine.